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Abstract
Background: Recent studies suggest that angiotensin-converting enzyme (ACE) inhibitors may
have beneficial effects for patients at risk for some types of infections. We examined the effect of
prior outpatient use of ACE inhibitors on mortality for patients hospitalized with community-
acquired pneumonia.
Methods: A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible
subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge
ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or
transferred from another acute care hospital. Subjects were considered to be on a medication if
they were taking it at the time of presentation.
Results: Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days
and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and
14% were high risk. In the multivariable conditional logistic regression analysis, after adjusting for
potential confounders, the use of ACE inhibitors at presentation (odds ratio 0.44, 95% confidence
interval 0.22–0.89) was significantly associated with 30-day mortality.
Conclusion: Prior outpatient use of an ACE inhibitor was associated with decreased mortality in
patients hospitalized with community-acquired pneumonia despite their use being associated with
comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as
well as research to determine the mechanism(s) of this protective effect.
Background
Community-acquired pneumonia is the seventh leading
cause of death and the leading cause of infectious death in
the United States [1]. Although mortality due to commu-
nity-acquired pneumonia decreased significantly with the
introduction of antibiotics in the 1950s since that time
mortality has been stable or increasing [2]. Despite this,
only a few new classes of antibiotics have been added to
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the armamentarium for treating community-acquired
pneumonia in the last 20 years and no new classes of
medications beyond antibiotics have been added since
the 1950s.
Recent studies have demonstrated that elderly patients
taking ACE inhibitors have significantly decreased rates of
aspiration pneumonia and may have decreased mortality
[3-5]. The hypothesized reason for this protective effect is
an increase in substance P which accentuates the cough
reflex. Other studies have demonstrated significant
changes in systemic cytokine levels for subjects treated
with ACE inhibitors [6-8]. These cytokines play an impor-
tant role in host defense mechanisms for patients with
community-acquired pneumonia but under certain con-
ditions may lead to septic shock or acute respiratory dis-
tress syndrome (ARDS) [9-11].
The study aim was to assess the effects of prior outpatient
ACE inhibitor use on 30-day mortality for patients hospi-
talized with community-acquired pneumonia.
Methods
This a retrospective cohort study of patients hospitalized
with community-acquired pneumonia at 2 academic ter-
tiary care hospitals in San Antonio, Texas. Both hospitals
are teaching affiliates of the University of Texas Health Sci-
ence Center at San Antonio. The Institutional Review
Board of the University of Texas Health Science Center at
San Antonio approved the research protocol with exempt
status.
Study sites/inclusion and exclusion criteria
We identified all patients admitted to the study hospitals
between January 1, 1999 and December 1, 2002 with a
primary discharge diagnosis of pneumonia (ICD-9 codes
480.0–483.99 or 485–487.0) or secondary discharge diag-
nosis of pneumonia with a primary diagnosis of respira-
tory failure (518.81) or sepsis (038.xx). Subjects were
included if they were 1) greater than 18 years of age, 2)
had an admission diagnosis of community-acquired
pneumonia documented in the medical record, and 3)
had a radiographically confirmed infiltrate or other find-
ing consistent with community-acquired pneumonia on
chest x-ray or CT obtained within 24 hours of admission.
Exclusion criteria included 1) having been discharged
from an acute care facility within 14 days of admission, 2)
transfer after being admitted to another acute care hospi-
tal, and 3) being comfort measures only on this admis-
sion. If a subject was admitted more than once during the
study period, only the first hospitalization was abstracted
Data abstraction
Chart review data included: demographics, comorbid
conditions, physical examination findings, laboratory
data, and chest radiograph reports. In addition, data on
important processes of care measures for patients hospi-
talized with community-acquired pneumonia were also
abstracted: first dose of antibiotics within 8 hours of
admission, collection of blood cultures prior to antibiotic
administration, and obtaining blood cultures and oxygen
saturation measurement within 24 hours of presentation
[12]. Antimicrobial therapy was considered guideline-
concordant if it agreed with either the 2000 Infectious
Diseases Society of America or 2001 American Thoracic
Society guidelines [13,14]. Information on all outpatient
medications that were either 1) reported as currently
being taken by the patient at presentation, or 2) listed in
the electronic medical record, were recorded.
Mortality was assessed using information from the Texas
Department of Health and Department of Veteran Affairs
clinical database. Mortality status was assessed through
December 31, 2002.
Risk adjustment
The pneumonia severity index was used to assess severity
of illness at presentation [15]. The pneumonia severity
index is a validated prediction rule for 30-day mortality in
patients with community-acquired pneumonia. This rule
is based on three demographic characteristics, five comor-
bid illnesses, five physical examination findings, and
seven laboratory and radiographic findings from the time
of presentation. Patients are classified into five risk classes
with 30-day mortality ranging from 0.1% for class I to
27% for class V for patients enrolled in the PORT cohort
study [15].
Outcome
We used 30-day mortality as the outcome for this study.
Previous research has demonstrated that 30-day mortality
is primarily due to the community-acquired pneumonia
rather than other co-existing co-morbid conditions
[16,17]. Therefore by using 30-day mortality as our out-
come we are able to minimize the effect of the ACE inhib-
itor use on other co-morbid conditions.
Statistical analyses
Univariate statistics were used to test the association of
sociodemographic and clinical characteristics with all-
cause 30-day mortality. Categorical variables were ana-
lyzed using the Chi-square test and continuous variables
were analyzed using Student's t-test.
A propensity score technique was used to balance covari-
ates associated with ACE inhibitor use between groups
[18,19]. The use of the propensity score techniqueBMC Pulmonary Medicine 2005, 5:12 http://www.biomedcentral.com/1471-2466/5/12
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provides a way, in non-randomized studies, to control for
pretreatment differences by defining sets of comparable
patients. The propensity score was derived from a logistic
regression model, and a dichotomous indicator variable
indexing whether a patient was on an ACE inhibitor was
our dependent variable. The covariates used to develop
the propensity score included the pneumonia severity
index (which includes comorbid conditions such as con-
gestive heart failure and chronic renal insufficiency), his-
tory of hypertension, and history of diabetes mellitus.
A multivariable conditional logistic regression model was
derived with 30-day mortality as the dependent variable,
and the propensity score as the matching variable [20].
The independent variables in the model were the use of
ACE inhibitor at presentation, and process of care meas-
ures (initial antibiotics within 8 hours and obtaining
blood cultures prior to initial dose of antibiotics, and
whether antimicrobial therapy was guideline concord-
ant). Interactions were assessed using cross-product terms
between the medications and all of the other variables
retained in the models. No significant interactions terms
were noted, so they were excluded from the final models.
All analyses were performed using STATA version 8 (Stata
Corporation, College Station, Texas).
Results
Data was abstracted on 787 patients at the two hospitals.
The mean age was 60 years with a standard deviation of 16
years. The population was 79% male, 84% were admitted
Table 1: Subject Demographic and Clinical Characteristics by 30-Day Mortality*
30-Day Mortality
Variable Alive (n = 714) Dead (n = 72) p-value
Age, years +/- standard deviation 60.2+/-16.4 62.9 +/-16.4 0.09
Men 561 (79) 60 (83) 0.3
Nursing home resident 41 (6) 13 (18) <0.001
Emergency department admission 598 (84) 58 (81) 0.5
Admitted to intensive care ≤ 24 hours 118 (17) 36 (50) <0.001
Preexisting Comorbid Conditions
Congestive heart failure 105 (15) 18 (25) 0.02
Chronic pulmonary disease 195 (27) 23 (31) 0.4
History of stroke 93 (13) 12 (17) 0.4
Chronic liver disease 83 (12) 11 (15) 0.4
History of malignancy 58 (8) 20 (28) <0.001
Renal insufficiency 74 (10) 13 (18) 0.05
History, Physical, Laboratory, and Radiographic Data
Altered mental status 68(10) 17(24) <0.001
Respiratory rate > 30 per minute 71 (10) 11 (15) 0.2
Systolic blood pressure < 90 mmHg 16 (2) 5 (7) 0.02
Heart rate > 125 per minute 86 (12) 19 (26) 0.001
Temperature < 95° or > 104° 19 (3) 2 (3) 0.9
Arterial pH < 7.35 37 (5) 12 (17) <0.001
Arterial oxygenation < 90% 149 (21) 27 (38) 0.001
Hematocrit < 30% 64 (9) 8 (11) 0.5
Blood urea nitrogen > 30 mg/dL 135 (19) 33 (46) <0.001
Serum glucose > 250 mg/dL 71 (10) 5 (7) 0.4
Serum sodium < 130 meq/L 98 (14) 18 (25) 0.01
Pleural effusion 160 (11) 29 (35) 0.001
Pneumonia Severity Index
Class I-III 393 (54) 16 (22)
Class IV 240 (34) 26 (36)
Class V 82 (12) 30 (42) <0.001
Processes of Care
Initial antibiotics within 4 hours 201 (28) 22 (31) 0.7
Initial antibiotics within 8 hours 358 (50) 36 (50) 1.0
Blood cultures prior to antibiotics 540 (76) 55 (76) 0.9
Oxygenation assessed ≤ 24 hours 538 (75) 65 (90) 0.004
Guideline-concordant antibiotics 574 (80) 51 (71) 0.05
Outpatient Medications
ACE inhibitor 183 (25) 11 (15) 0.05
* Data are presented as number (%) or mean +/-standard deviationBMC Pulmonary Medicine 2005, 5:12 http://www.biomedcentral.com/1471-2466/5/12
Page 4 of 6
(page number not for citation purposes)
through the emergency department, and 20% were admit-
ted to the intensive care unit within the first 24 hours after
admission. Mortality was 9.2% at 30-days and 13.6% at
90-days. By pneumonia severity index, 52% were low risk
(pneumonia severity index classes I-III), 34% were mod-
erate risk (pneumonia severity index class IV), and 14%
were high risk (pneumonia severity index class V). Regard-
ing community-acquired pneumonia-related processes of
care, 28% received the initial dose of antibiotics within 4
hours of presentation and an additional 22% received the
initial antibiotic dose within 8 hours, 76% of patients had
blood cultures obtained within 24 hours and prior to anti-
biotics, and oxygenation was assessed at presentation in
91%.
Table 1 shows the demographic factors, clinical character-
istics, and processes of care data for this population by 30-
day mortality. In the univariate analysis numerous indi-
vidual components of the pneumonia severity index were
significantly associated with 30-day mortality including
age, nursing home residency, history of congestive heart
failure, history of malignancy, altered mental status, systo-
lic blood pressure < 90 mmHg, tachycardia> 125 beats per
minute, arterial acidosis, elevated blood urea nitrogen 30
mg/dl, serum sodium < 130 meq/l, and pleural effusion
on chest radiograph. The only processes of care that were
statistically significant were the assessment of oxygena-
tion within 24 hours or presentation and use of guideline-
concordant antibiotics. ACE inhibitor use was signifi-
cantly associated (p = 0.05) with 30-day mortality.
Table 2 demonstrates clinical and demographic variables
and the association with use/non-use of ACE inhibitors at
presentation. Co-morbid conditions and demographic
variables significantly associated with ACE inhibitor use
included coronary artery disease, higher age, diabetes mel-
Table 2: Use versus non-use of ACE inhibitors by demographic and clinical characteristics*
ACE Inhibitor Use
Variable Not on ACE inhibitor
 (n= 593)
On ACE inhibitor 
(n=194)
p-value
Age, years +/- standard deviation 58.2 +/-16.9 67.1+/-13.6 <0.001
Men 467 (79) 154(80) 0.8
Nursing home resident 43(7) 11(6) 0.4
Emergency department admission 498(84) 158(81) 0.38
Admitted to intensive care ≤ 24 hours 116(20) 38(20) 1.0
Preexisting Comorbid Conditions
Diabetes Mellitus 138(23) 92(47) <0.001
Coronary artery disease 132(22) 98(51) <0.001
Chronic pulmonary disease 151(25) 67(35) <0.001
Current tobacco use 200(31) 35(18) <0.001
Congestive heart failure 59(10) 64(33) <0.001
History of stroke 67(11) 38(20) 0.003
Chronic liver disease 82(14) 12(6) 0.004
History of malignancy 57(10) 21(11) 0.6
Renal insufficiency 54(9) 33(17) 0.002
History, Physical, Laboratory, and Radiographic Data
Altered mental status 62(10) 23(12) 0.6
Respiratory rate > 30 per minute 67(11) 15(8) 0.16
Systolic blood pressure < 90 mmHg 17(3) 4(2) 0.5
Heart rate > 125 per minute 87(15) 18(9) 0.06
Temperature < 95° or > 104° 18(3) 3(2) 0.26
Arterial pH < 7.35 33(6) 16(8) 0.18
Arterial oxygenation < 90% 128(22) 48(25) 0.4
Hematocrit < 30% 59(10) 13(7) 0.17
Blood urea nitrogen > 30 mg/dL 110(19) 58(30) <0.001
Serum glucose > 250 mg/dL 50(8) 26(13) 0.04
Serum sodium < 130 meq/L 95(16) 21(11) 0.08
Pleural effusion 141(24) 48(25) 0.8
Pneumonia Severity Index
Class I-III 332(56) 77(40)
Class IV 187(32) 79(41)
Class V 74(12) 38(20) <0.001
* Data are presented as number (%) or mean +/-standard deviationBMC Pulmonary Medicine 2005, 5:12 http://www.biomedcentral.com/1471-2466/5/12
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litus, chronic obstructive pulmonary disease, not cur-
rently smoking, congestive heart failure, prior stroke, no
history of liver disease, and chronic renal disease. Physical
exam and laboratory findings associated with ACE inhib-
itor use included decreased numbers of patients with
heart rates > 125, higher rates of elevated blood urea nitro-
gen > 30 mg/dL, lower rates of serum hematocrit < 30%,
and higher rates of serum glucose > 250 mg/dL. Of the
787 subjects 194 (25%) were on ACE inhibitors. There
was greater ACE inhibitor use in those who were in the
moderate (30%, n = 74) and severe (34%, n = 38) risk
groups versus those with low severity of illness (19%, n =
77), p < 0.001.
In the multivariable conditional logistic regression analy-
sis after adjusting for potential confounders the use of
ACE inhibitors at presentation (odds ratio (OR) 0.44,
95% confidence interval (CI) 0.22–0.89) was associated
with 30-day mortality. The other variables in the model
included initial antibiotics within 4 hours (OR 1.09, 95%
CI 0.64-1.85), obtaining blood cultures prior to antibiot-
ics (OR 1.10, 95% CI 0.6-1.9), oxygenation assessment
within 24 hours (OR 1.31, 95% CI 0.5–3.4), and use of
guideline-concordant antimicrobial therapy (OR 0.6,
0.35–1.05).
Discussion
We found that prior outpatient use of ACE inhibitors was
associated with decreased 30-day mortality for subjects
hospitalized with community-acquired pneumonia. Our
findings provide further support to other studies that
demonstrate that ACE inhibitor use is associated with
decreased mortality for patients with pneumonia.
There are several potential mechanisms for a beneficial
effect on mortality for patients on ACE inhibitors. ACE
inhibitors have been shown in clinical studies to
increased serum levels of substance P, which is hypothe-
sized to lead to a better gag reflex and increased clearance
of secretions [3-5]. Our study specifically excluded
patients with a discharge diagnosis of aspiration pneumo-
nia; however, this diagnosis can be clinically difficult to
distinguish from community-acquired pneumonia. Other
studies have demonstrated that ACE inhibitors have sig-
nificant immunomodulatory effects on circulating
cytokines [6-8]. Therefore the beneficial effect may be due
to blunting of the cytokine response so that these patients
have lower rates of sepsis and/or ARDS.
Although our study was retrospective and subject to the
recognized limitations of such studies, we carefully assem-
bled our cohort from complete patient discharge data to
avoid ascertainment bias. Additionally, during chart
abstraction we encountered a very small amount (<5%) of
missing data. Our sample was predominantly men due to
the inclusion of a VA hospital and it is possible, but
unlikely, that women may have differential responsive-
ness to ACE inhibitors as compared to men. In addition
we are unable to examine whether or not there was signif-
icant amounts of non-prescription or non-compliance of
ACE inhibitor therapy due to economic considerations.
Also we are unable to assess factors such as inpatient con-
tinuation of the ACE inhibitor or the dose effect due to the
design of this study. Further research is needed to examine
these factors. Finally, as in any non-experimental study,
we are unable to state conclusively that the prior outpa-
tient use of ACE inhibitors is the cause of decreased mor-
tality in this cohort. However, since patients on ACE
inhibitors had significantly higher severity of illness
scores at presentation we feel that we have good evidence
that these medications may have beneficial effects for
patients hospitalized with community-acquired
pneumonia.
Conclusion
In conclusion, our study finds that prior outpatient use of
ACE inhibitors reduces mortality for patients with com-
munity-acquired pneumonia. Our results add further
strength to the existent recommendations to use ACE
inhibitors in patients with congestive heart failure, diabe-
tes mellitus, and renal disease, since these patients are at
higher risk for either contracting pneumonia or dying
from pneumonia when they do contract it. Future
research, especially randomized clinical trials, are needed
to examine whether either ACE inhibitors are protective
when used in an inpatient setting for patients lacking tra-
ditional indications for the use of these medications.
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